
Gilenya has become the first oral multiple sclerosis drug to be launched in the UK. Gilenya (fingolimod) is licenced to …

Novartis’ Gilenya has become the first oral multiple sclerosis drug to be approved in Europe. Gilenya (fingolimod) is now licensed …

Merck Serono has withdrawn its European licence application for multiple sclerosis drug Movectro. Movectro (cladribine) is a new oral treatment …
Novartis’ oral multiple sclerosis Gilenya could be on the European market in just three months after winning the backing of …
Novartis’ new multiple sclerosis treatment Gilenya has been approved by the FDA, and is set to significantly alter the way …